Abstract:AIM:To investigate the role of bone marrow-derived endothelial progenitor cells（EPCs） in the angiogenesis of hepatocellular carcinoma（HCC）.METHODS:The bone marrow of HCC mice was reconstructed by transplanting green fluorescent protein（GFP） + bone marrow cells.The concentration of circulating EPCs was determined by colony-forming assays and fluorescence-activated cell sorting.Serum and tissue levels of vascular endothelial growth factor（VEGF） and colony-stimulating factor（CSF） were quantified by enzyme-linked immunosorbent assay.The distribution of EPCs in tumor and tumor-free tissues was detected by immunohistochemistry and real-time polymerase chain reaction.The incorporation of EPCs into hepatic vessels was examined by immunofluorescence and immunohistochemistry.The proportion of EPCs in vessels was then calculated.RESULTS:The HCC model was successful established.The flow cytometry analysis showed the mean percentage of CD133CD34 and CD133VEGFR2 double positive cells in HCC mice was 0.45% ± 0.16% and 0.20% ± 0.09% respectively.These values are much higher than in the sham-operation group（0.11% ± 0.13%,0.05% ± 0.11%,n = 9） at 14 d after modeling.At 21 d,the mean percentage of circulating CD133CD34 and CD133VEGFR2 cells is 0.23% ± 0.19%,0.25% ± 0.15% in HCC model vs 0.05% ± 0.04%,0.12% ± 0.11% in control.Compared to the transient increase observed in controls,the higher level of circulating EPCs were induced by HCC.In addition,the level of serum VEGF and CSF increased gradually in HCC,reaching its peak 14 d after modeling,then slowly decreased.Consecutive sections stained for the CD133 and CD34 antigens showed that the CD133+ and CD34+ VEGFR2 cells were mostly recruited to HCC tissue and concentrated in tumor microvessels.Under fluorescence microscopy,the bone-marrow（BM）-derived cells labeled with GFP were concentrated in the same area.The relative levels of CD133 and CD34 gene expression were elevated in tumors,around 5.0 and 3.8 times that of the tumor free area.In frozen liver sections from HCC mice,cells co-expressing CD133 and VEGFR2 were identified by immunohistochemical staining using anti-CD133 and VEGFR2 antibodies.In tumor tissue,the double-positive cells were incorporated into vessel walls.In immunofluorescent staining.These CD31 and GFP double positive cells are direct evidence that tumor vascular endothelial cells（VECs） come partly from BM-derived EPCs.The proportion of GFP CD31 double positive VECs（out of all VECs） on day 21 was around 35.3% ± 21.2%.This is much higher than the value recorded on day 7 group（17.1% ± 8.9%）.The expression of intercellular adhesion molecule 1,vascular adhesion molecule 1,and VEGF was higher in tumor areas than in tumor-free tissues.CONCLUSION:Mobilized EPCs were found to participate in tumor vasculogenesis of HCC.Inhibiting EPC mobilization or recruitment to tumor tissue may be an efficient strategy for treating HCC.

High Expression of Endothelial Progenitor Cell-Induced Angiogenic Markers is Associated with Bile Acid Levels in HCC.

Relationship of HDGF or VEGF expression with hepatocellular carcinoma angiogenesis:report of 108 cases

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

Endothelial Precursor Cells Promote Angiogenesis in Hepatocellular Carcinoma

Identification and Clinical Significance of Mobilized Endothelial Progenitor Cells in Tumor Vasculogenesis of Hepatocellular Carcinoma

Mechanism of Endothelial Progenitor Cell Recruitment into Neo-Vessels in Adjacent Non-Tumor Tissues in Hepatocellular Carcinoma

High Epithelial Cell Adhesion Molecule–Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization

[The Effect of Pro-Angiogenic Factors and Their Receptors on Angiogenesis in Hepatocellular Carcinoma].

Expression of angiopoietins, Tie2 and vascular endothelial growth factor in anglogenesis and progression of hepatocellular carcinoma

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

Prognostic role of expression of angiogenesis markers in hepatocellular carcinoma: A bioinformatics analysis

Altered Epidermal Fatty Acid-Binding Protein Expression in Hepatocellular Carcinoma Predicts Unfavorable Outcomes

Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection.

Protein Expression Profiling of Vascular Endothelial Growth Factor and Its Receptors Identifies Subclasses of Hepatocellular Carcinoma and Predicts Survival

Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma

Hypoxic and Highly Angiogenic Non-Tumor Tissues Surrounding Hepatocellular Carcinoma: the ‘niche’ of Endothelial Progenitor Cells

Expression and Clinical Significance of CD146 and VEGF in Hepatocellular Carcinoma

Vascular Endothelial Growth Factor Receptor-2 and Its Association with Tumor Immune Regulatory Gene Expression in Hepatocellular Carcinoma.

The Clinical Significance of Endothelin Receptor Type B in Hepatocellular Carcinoma and Its Potential Molecular Mechanism

Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF As a Prognostic Factor in Patients with Hepatocellular Carcinoma

Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.